


Details:
The most important finding from that clinical trial was that ropocamptide (LL-37) shows a significant effect in the patient subgroup with large wounds (≥10 cm2).
Lead Product(s): Ropocamptide
Therapeutic Area: Podiatry Product Name: LL-37
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2022
Details:
EscharEx (proteolytic enzymes enriched bromelain) is a bioactive therapy for debridement of chronic and other hard-to-heal wounds in advanced stages of clinical development, is easy-to-use concentrate of proteolytic enzymes enriched in bromelain for topical daily applications.
Lead Product(s): Bromelain Enriched Proteolytic Enzyme
Therapeutic Area: Podiatry Product Name: EscharEx
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2022
Details:
Bisphosphocins are novel small protonated nucleotide derivative molecules that exert their antibacterial activity by depolarization and rupture of the bacterial cell membranes, causing rapid bacterial cell death.
Lead Product(s): Bisphosphocin
Therapeutic Area: Podiatry Product Name: Nu-3
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2022
Details:
U.S. phase 2 trial of EscharEx (Proteolytic enzymes enriched in bromelain) as a non-surgical rapid and effective debridement agent with the potential to improve on the current standard of care for chronic wound management.
Lead Product(s): Proteolytic Enzymes Enriched In Bromelain
Therapeutic Area: Podiatry Product Name: EscharEx
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2021
Details:
The study is expected to enroll 120 patients at approximately 20 clinical sites, primarily in U.S. Study participants are randomized to either EscharEx, placebo control or non-surgical soc of either enzymatic or autolytic debridement, at ratio of 3:3:2, with 3 month follow-up.
Lead Product(s): Proteolytic Enzymes Enriched in Bromelain
Therapeutic Area: Podiatry Product Name: EscharEx
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2021
Details:
The mechanism of action of EscharEx is mediated by the proteolytic enzymes that cleave and remove the necrotic tissue and prepare the wound bed for healing. EscharEx is an investigational product, currently under a U.S. phase 2 adaptive design study.
Lead Product(s): Proteolytic Enzymes Enriched in Bromelain
Therapeutic Area: Podiatry Product Name: EscharEx
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2021
Details:
The objective of the study is to evaluate the clinical performance, safety, and pharmacology effect of EscharEx in debridement of lower leg ulcers (venous leg ulcers and diabetic foot ulcers) in up to 15 patients.
Lead Product(s): Proteolytic enzymes enriched in bromelain
Therapeutic Area: Podiatry Product Name: EscharEx
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2021